Xenetic Biosciences, Inc. Price & Performance (XBIO)

Xenetic Biosciences reported a first-quarter loss of $903,000, or 59 cents per share, with revenue reaching $593,000. This result fell short of analyst expectations, which had forecast a loss of 72 cents per share but higher revenue. The company remains under close watch as it navigates ongoing challenges.12

Renaissance Technologies increased its holdings in Xenetic Biosciences by 61% in Q4, now owning 1.66% of the company. Institutional investors collectively hold over 15% of Xenetic, signaling growing interest despite the biotech firm's recent quarterly losses and volatile stock performance.34

Xenetic Biosciences exhibits a beta of 2.31, making it significantly more volatile than the S&P 500. Institutional and insider ownership levels are above peers, but analysts currently rate the stock as a hold, with less upside potential compared to competitors like Daré Bioscience.4